Search the Newsreel

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which …

What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders

Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings

Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this …

Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading …

Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A

Tushar Patel has filed an Amendment No. 6 to his Schedule 13D, disclosing beneficial ownership of 61,341,678 shares of Amneal Pharmaceuticals Class A common stock, representing 17.6% of the outstanding shares. This updated ownership stake reflects shares acquired through the recent Kashiv BioSciences acquisition, …

Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares

Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC for $375 million in cash and 28,942,098 shares of Class A Common Stock. This transaction has resulted in Chintu Patel becoming the beneficial owner of 32,576,528 shares, representing 9.4% of Amneal's Class A …

Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal

Amneal Pharmaceuticals director Gautam Patel reported an indirect acquisition of 283,632 Class A common shares on August 10, 2026. These shares were received by limited liability companies he manages as part of Amneal's acquisition of Kashiv BioSciences, LLC. Following this transaction, Patel directly holds …

Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal

Amneal Pharmaceuticals' Co-CEO, Chirag K. Patel, through entities he manages, acquired 6,381,734 Class A common shares on August 10, 2026. This share issuance was part of Amneal's acquisition of Kashiv BioSciences, LLC. After the transaction, Patel holds 1,393,470 shares directly and 21,269,420 shares indirectly …

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution …

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains …

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches …

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, …

1 Healthcare Stock Worth Your Attention and 2 We Ignore

1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over …

Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?

Amneal Pharmaceuticals (AMRX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The Zacks …

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Acadia Pharmaceuticals (ACAD) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a …

Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality

Amneal Pharmaceuticals reported healthy earnings, but the stock price remained stable. The company's profit was impacted by US$81m in unusual expenses, which are likely one-off events, suggesting higher future profits. The article highlights that these unusual items might cause Amneal Pharmaceuticals' statutory profit to …

UBS raises Amneal Pharmaceuticals price target on biosimilar growth

UBS has increased its price target for Amneal Pharmaceuticals Inc. to $25.00 from $23.00, maintaining a Buy rating. This adjustment follows the company's strong second-quarter earnings beat and raised guidance, despite a recent stock pullback. UBS anticipates significant growth from Amneal's biosimilar and generic …

Did Strong Q2 Results and Higher 2026 Revenue Guidance Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative?

Arrowstreet Capital Limited Partnership Trims Stake in Amneal Pharmaceuticals, Inc. $AMRX

Amneal Pharma A earnings beat by $0.07, revenue topped estimates

Amneal Pharma A (NASDAQ: AMRX) reported strong second-quarter results, surpassing analyst estimates with EPS of $0.300 and revenue of $796.2 million. The company also provided optimistic full-year 2026 guidance, expecting EPS between $0.960-$1.060 and revenue between $3.100B-$3.200B. AMRX stock has shown significant growth, increasing …

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

Amneal (AMRX) Stock Looks About Fair Value On Current Earnings

First Trust Advisors LP Acquires 116,873 Shares of Amneal Pharmaceuticals, Inc. $AMRX

AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance

AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 …

Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure

Amneal Pharmaceuticals (AMRX) reported a strong Q2 with increased revenue and adjusted EPS, leading to a raised full-year outlook. While the company is transitioning towards higher-margin biosimilars and injectables, investor concern centers on the sustainability of this profit momentum given increased capital expenditure and …

Amneal Pharmaceuticals Inc (AMRX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal Pharmaceuticals AMRX reported second-quarter 2026 adjusted earnings of 30 cents per share, which beat the Zacks Consensus Estimate of 24 cents. Earnings increased 20% year over year, driven by strong performance across the company's three business segments. Total revenues of $796 million in …

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding the company is "growing as one of the America's leading …

Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip

Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its …

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Amneal Pharmaceuticals (AMRX) reported revenue of $796.2 million, up 9.9% over the same period last year. EPS came in at $0.30, compared to $0.25 in the year-ago quarter. The reported revenue represents a surprise of +3.7% over the …

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …